<DOC>
	<DOCNO>NCT01873768</DOCNO>
	<brief_summary>Tranexamic acid ( TXA ) ε-aminocaproic acid ( EACA ) two drug show limit blood loss follow major surgery , cardiac orthopedic procedure . Yet compare tranexamic acid ( TXA ) , research clinical impact ε-aminocaproic acid ( EACA ) total knee arthroplasty ( TKA ) limit . The primary aim study determine whether TXA EACA provide similar blood decreasing effect follow TKA whether one drug provide superior effect reduce patient ' blood loss .</brief_summary>
	<brief_title>Clinical Efficacy Tranexamic Acid ε-Aminocaproic Acid Reducing Blood Loss Following Total Knee Replacement</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Aminocaproic Acid</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Persons age 18 90 year schedule undergo unilateral total knee replacement surgery NonEnglish speaking individual Individuals history deep vein thrombosis pulmonary embolism within one year Individuals history coagulopathy Heart stent within one year Preoperative autologous blood donation Unwilling unable take Coumadin deep vein thrombosis ( DVT ) prophylaxis Received nonsteroidal antiinflammatory drug ( NSAID ) platelet antiaggregant treatment within five day prior surgery Preoperative creatinine great 1.5mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Tranexamic acid</keyword>
	<keyword>6-Aminocaproic Acid</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Antifibrinolytic Agents</keyword>
	<keyword>Fibrin Modulating Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Coagulants</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>